お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
948701

日本の整形外科バイオマテリアル市場(2020年~2026年): MedSuite

Orthopedic Biomaterials Market Report Suite | Japan | 2020 - 2026 | MedSuite

出版日: | 発行: iData Research Inc. | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円

※ Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

日本の整形外科バイオマテリアル市場(2020年~2026年): MedSuite
出版日: 2020年02月14日
発行: iData Research Inc.
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
担当者のコメント
当サービス(MedSuite)は、セグメント別(MedCore)にご注文可能です。(USD3,995/1セグメント)。まずはサンプル送付させていただきますので、ご希望のセグメントをお知らせください。
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

2019年における日本の整形外科バイオマテリアルの市場は4億2690万ドルと推計されており、予測期間中は-0.4%のCAGRで推移すると予測されています。製品の差別化の不足からコモディティ化を招き、技術革新や新製品の開発を阻害しています。また日本でのHA粘剤製品の価格は導入以来大幅に低下し、世界でも最低水準となっています。一方、2019年における日本の総人口の約29%は65歳以上であり、予測期間中は団塊の世代が加わることで、この割合は着実に増加します。この人口層の増加は、整形外科バイオマテリアル市場の成長を刺激すると予測されています。

当レポートでは、日本の整形外科バイオマテリアルの市場を調査し、市場背景、製品ポートフォリオ、骨移植片、脱灰骨基質(DBM)移植片、合成骨などの骨移植片代替品、整形外科用増殖因子、ヒアルロン酸関節内補充液の市場規模の推移・予測、これらの材料を用いた整形外科処置件数、市場成長への各種影響因子の分析、競合環境、市場シェア、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

日本の整形外科バイオマテリアル市場:市場概要

競合分析

動向

市場開発

手術件数

対象市場

改訂履歴

調査手法

製品の評価

  • イントロダクション
  • 製品ポートフォリオ
  • 規制上の課題・リコール
  • 臨床試験
    • 骨移植代替物
    • 増殖因子
    • ヒアルロン酸関節内補充液

日本の整形外科バイオマテリアル市場:市場概要

  • イントロダクション
    • 骨移植代替物
    • 増殖因子
    • ヒアルロン酸関節内補充液
  • 為替レート
  • 市場概要・動向分析
  • 成長推進因子・抑制因子
  • 企業シェア分析
  • M&A
  • 企業プロファイル
    • Anika Therapeutics
    • Bioventus
    • DePuy Synthes
    • Ferring Pharmaceuticals
    • Fidia Pharmaceuticals
    • Genzyme (Sanofi Group)
    • Harvest Technologies (Terumo BCT)
    • Integra LifeSciences
    • Medtronic
    • Musculoskeletal Transplant Foundation (MTF)
    • NuVasive
    • Orthofix
    • RTI Surgical
    • Stryker
    • Vericel Corporation
    • Zimmer Biomet
  • SWOT分析

手術件数

  • イントロダクション
  • 手術件数:タイプ別
    • 骨移植術
    • ヒアルロン酸補充

整形外科用骨移植代替物市場

  • イントロダクション
  • 市場分析・予測
  • 成長推進因子・抑制因子
  • 企業シェア分析

ヒアルロン酸関節内補充市場

  • イントロダクション
    • メリット
    • 滑液
  • 市場概要
  • 市場分析・予測
    • 総市場
    • 3回注射
    • 5回注射
  • 成長推進因子・抑制因子
  • 企業シェア分析

略語

図表

LIST OF CHARTS

  • Chart 1 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 - 2026 2
  • Chart 1 2: Orthopedic Biomaterials Market Overview, Japan, 2019 & 2026 2
  • Chart 3 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 - 2026 68
  • Chart 3 2: Orthopedic Biomaterials Market Breakdown, Japan, 2019 69
  • Chart 3 3: Orthopedic Biomaterials Market Breakdown, Japan, 2026 70
  • Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Japan, 2017 - 2026 72
  • Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019 78
  • Chart 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 - 2026 120
  • Chart 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 - 2026 122
  • Chart 4 3: Autograft Orthopedic Procedures by Indication, Japan, 2016 - 2026 126
  • Chart 4 4: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 - 2026 129
  • Chart 4 5: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 - 2026 131
  • Chart 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 - 2026 134
  • Chart 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 - 2026 136
  • Chart 5 3: Spine Synthetic Market, Japan, 2016 - 2026 138
  • Chart 5 4: Cervical Spine Synthetic Market, Japan, 2016 - 2026 140
  • Chart 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 - 2026 142
  • Chart 5 6: Trauma Synthetic Market, Japan, 2016 - 2026 144
  • Chart 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 - 2026 146
  • Chart 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 - 2026 148
  • Chart 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 - 2026 150
  • Chart 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 - 2026 152
  • Chart 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 - 2026 154
  • Chart 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 - 2026 156
  • Chart 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 - 2026 158
  • Chart 5 14: Oncology Synthetic Market, Japan, 2016 - 2026 160
  • Chart 5 15: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019 166
  • Chart 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 - 2026 172
  • Chart 6 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2019 173
  • Chart 6 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2026 174
  • Chart 6 4: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 176
  • Chart 6 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 178
  • Chart 6 6: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 180
  • Chart 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan, 2019 186

LIST OF FIGURES

  • Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Japan, 2019 3
  • Figure 1 2: Companies Researched in this Report 4
  • Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Japan 5
  • Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Japan, 2017 - 2019 6
  • Figure 1 5: Orthopedic Biomaterials Procedures Covered, Japan 7
  • Figure 1 6: Orthopedic Biomaterials Markets Covered, Japan 8
  • Figure 1 7: Version History 8
  • Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4) 26
  • Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4) 27
  • Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4) 28
  • Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4) 29
  • Figure 2 5: Growth Factor Products by Company 34
  • Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company 37
  • Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit 38
  • Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc 38
  • Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty 39
  • Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc 39
  • Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty 39
  • Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules 40
  • Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules 40
  • Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT 40
  • Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate) 41
  • Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease 42
  • Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites. 42
  • Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO. 43
  • Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System 43
  • Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation 44
  • Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction 44
  • Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy) 45
  • Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP) 45
  • Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™ 46
  • Figure 2 25: AttraX® Putty vs. Autograft in XLIF® 47
  • Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine 47
  • Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine 48
  • Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System 48
  • Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy 49
  • Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion 49
  • Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO) 50
  • Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material 50
  • Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal 51
  • Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® 51
  • Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation 52
  • Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2 52
  • Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody) 53
  • Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 53
  • Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation 54
  • Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment 54
  • Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA) 55
  • Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft 55
  • Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport 56
  • Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery 56
  • Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02) 57
  • Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK) 57
  • Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee 58
  • Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant 59
  • Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection 59
  • Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans 60
  • Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA) 60
  • Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401) 61
  • Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX) 61
  • Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA) 62
  • Figure 3 1: Currency Exchange Rate, 2019 65
  • Figure 3 2: Orthopedic Biomaterials Market by Segment, Japan, 2016 - 2026 (US$M) 67
  • Figure 3 3: Orthopedic Biomaterials Market by Segment, Japan, 2016 - 2026 (JP¥M) 67
  • Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, Japan, 2016 - 2026 71
  • Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, Japan, 2019 74
  • Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019 77
  • Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2) 99
  • Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2) 100
  • Figure 3 9: SWOT Analysis, Bioventus (1 of 2) 101
  • Figure 3 10: SWOT Analysis, Bioventus (2 of 2) 102
  • Figure 3 11: SWOT Analysis, DePuy Synthes 103
  • Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals 104
  • Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals 105
  • Figure 3 14: SWOT Analysis, Genzyme (Sanofi) 106
  • Figure 3 15: SWOT Analysis, Harvest Technologies 107
  • Figure 3 16: SWOT Analysis, Integra LifeSciences 108
  • Figure 3 17: SWOT Analysis, Medtronic 109
  • Figure 3 18: SWOT Analysis, MTF 110
  • Figure 3 19: SWOT Analysis, NuVasive 111
  • Figure 3 20: SWOT Analysis, Orthofix 112
  • Figure 3 21: SWOT Analysis, RTI Surgical 113
  • Figure 3 22: SWOT Analysis, Stryker 114
  • Figure 3 23: SWOT Analysis, Vericel Corporation 115
  • Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2) 116
  • Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2) 117
  • Figure 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 - 2026 119
  • Figure 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 - 2026 121
  • Figure 4 3: Units per Procedure by Indication, Bone Graft Substitute Market, Japan, 2016- 2026 123
  • Figure 4 4: Autograft Orthopedic Procedures by Indication, Japan, 2016 - 2026 (1 of 2) 124
  • Figure 4 5: Autograft Orthopedic Procedures by Indication, Japan, 2016 - 2026 (2 of 2) 125
  • Figure 4 6: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 - 2026 (1 of 2) 127
  • Figure 4 7: Synthetic Orthopedic Bone Grafting Procedures, Japan, 2016 - 2026 (2 of 2) 128
  • Figure 4 8: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 - 2026 130
  • Figure 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 - 2026 133
  • Figure 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 - 2026 (US$M) 135
  • Figure 5 3: Spine Synthetic Market, Japan, 2016 - 2026 137
  • Figure 5 4: Cervical Spine Synthetic Market, Japan, 2016 - 2026 139
  • Figure 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 - 2026 141
  • Figure 5 6: Trauma Synthetic Market, Japan, 2016 - 2026 143
  • Figure 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 - 2026 145
  • Figure 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 - 2026 147
  • Figure 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 - 2026 149
  • Figure 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 - 2026 151
  • Figure 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 - 2026 153
  • Figure 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 - 2026 155
  • Figure 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 - 2026 157
  • Figure 5 14: Oncology Synthetic Market, Japan, 2016 - 2026 159
  • Figure 5 15: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, Japan, 2019 163
  • Figure 5 16: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019 165
  • Figure 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 - 2026 (US$M) 170
  • Figure 6 2: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 - 2026 (JP¥M) 171
  • Figure 6 3: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 175
  • Figure 6 4: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 177
  • Figure 6 5: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 - 2026 179
  • Figure 6 6: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Japan, 2019 182
  • Figure 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan, 2019 185
目次
Product Code: iDATA_JPOB20_MS

The Japanese orthopedic biomaterials market was valued at $426.9 million in 2019. This is expected to fluctuate over the forecast period with a -0.4% CAGR.

A lack of product differentiation across similar injection cycle products has led to commoditization, which has stifled innovation and the further development of new products. The prices of HA viscosupplementation products in Japan have drastically decreased since their introduction and are among the lowest in the world.

Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, approximately 29% of the Japanese population were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65. Growth of this population is expected to stimulate growth across all segments of the orthopedic biomaterials market.

The full report suite on the Japan market for orthopedic biomaterials includes bone graft substitutes, which are represented by synthetics and DBM allografts. DBM allografts are discussed qualitatively. This report also includes hyaluronic acid (HA) viscosupplementation.

TABLE OF CONTENTS I

LIST OF FIGURES VII

LIST OF CHARTS XII

EXECUTIVE SUMMARY 1

JAPANESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 3

MARKET TRENDS 5

MARKET DEVELOPMENTS 6

PROCEDURE NUMBERS 7

MARKETS INCLUDED 8

VERSION HISTORY 8

RESEARCH METHODOLOGY 9

  • Step 1: Project Initiation & Team Selection 9
  • Step 2: Prepare Data Systems and Perform Secondary Research 12
  • Step 3: Preparation for Interviews & Questionnaire Design 14
  • Step 4: Performing Primary Research 15
  • Step 5: Research Analysis: Establishing Baseline Estimates 17
  • Step 6: Market Forecast and Analysis 18
  • Step 7: Identify Strategic Opportunities 20
  • Step 8: Final Review and Market Release 21
  • Step 9: Customer Feedback and Market Monitoring 22

PRODUCT ASSESSMENT 23

  • 2.1 INTRODUCTION 23
  • 2.2 PRODUCT PORTFOLIOS 23
    • 2.2.1 Bone Graft Substitutes 24
    • 2.2.2 Growth Factors 30
      • 2.2.2.1 Other Products 33
    • 2.2.3 Hyaluronic Acid Viscosupplementation (HAV) 35
  • 2.3 REGULATORY ISSUES AND RECALLS 38
    • 2.3.1 Bone Graft Substitutes 38
      • 2.3.1.1 Allografts 38
      • 2.3.1.1.1 MTF 38
      • 2.3.1.2 DBM 38
      • 2.3.1.2.1 AlloSource 38
      • 2.3.1.2.2 SeaSpine 39
      • 2.3.1.2.3 RTI Surgical 39
      • 2.3.1.3 Synthetics 39
      • 2.3.1.3.1 Abyrx 39
      • 2.3.1.3.2 Zimmer Biomet 40
    • 2.3.2 Growth Factors 40
      • 2.3.2.1.1 Medtronic 40
    • 2.3.3 Hyaluronic Acid Viscosupplementation 41
      • 2.3.3.1 Three-injection 41
      • 2.3.3.1.1 Ferring Pharmaceuticals 41
  • 2.4 CLINICAL TRIALS 42
    • 2.4.1 Bone Graft Substitutes 42
      • 2.4.1.1 Allografts 42
      • 2.4.1.1.1 Providence Medical Technology 42
      • 2.4.1.1.2 The University of Texas Health Science 42
      • 2.4.1.1.3 University of Winchester 43
      • 2.4.1.2 BDM 43
      • 2.4.1.2.1 K2M 43
      • 2.4.1.2.2 Zimmer Biomet 44
      • 2.4.1.3 Synthetics 44
      • 2.4.1.3.1 Baxter 44
      • 2.4.1.3.2 Bonesupport 45
      • 2.4.1.3.3 DePuy Synthes 45
      • 2.4.1.3.4 NuVasive 47
      • 2.4.1.3.5 RTI surgical 47
      • 2.4.1.3.6 Sunstar GUIDOR 48
      • 2.4.1.4 Other materials and comparison 49
      • 2.4.1.4.1 Seoul National University Hospital. 49
      • 2.4.1.4.2 Sewon Cellontech 49
      • 2.4.1.4.3 SurgaColl Technologies Limited 50
      • 2.4.1.4.4 University of Colorado 50
      • 2.4.1.4.5 University of Padova 51
    • 2.4.2 Growth Factors 51
      • 2.4.2.1.1 Bioventus 51
      • 2.4.2.1.2 Cerapedics 52
      • 2.4.2.1.3 CGBio 52
      • 2.4.2.1.4 Isto 53
      • 2.4.2.1.5 Medtronic 53
      • 2.4.2.1.6 NuVasive 55
      • 2.4.2.1.7 Wright 55
      • 2.4.2.1.8 Others 56
    • 2.4.3 Hyaluronic Acid Viscosupplementation 57
      • 2.4.3.1.1 Anika Therapeutics 57
      • 2.4.3.1.2 Bioventus 58
      • 2.4.3.1.3 Cairo University 59
      • 2.4.3.1.4 Ferring Pharmaceuticals 59
      • 2.4.3.1.5 Federal University of Minas Gerais 60
      • 2.4.3.1.6 Fidia Pharma USA Inc. 60
      • 2.4.3.1.7 Istituto Ortopedico Rizzoli 61
      • 2.4.3.1.8 University Hospital 61
      • 2.4.3.1.9 Universidade Nova de Lisboa 62

JAPAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 63

  • 3.1 INTRODUCTION 63
    • 3.1.1 Bone Graft Substitutes 63
    • 3.1.2 Growth Factors 63
    • 3.1.3 Hyaluronic Acid (HA) Viscosupplementation 64
  • 3.2 CURRENCY EXCHANGE RATE 65
  • 3.3 MARKET OVERVIEW AND TREND ANALYSIS 66
  • 3.4 DRIVERS AND LIMITERS 73
    • 3.4.1 Market Drivers 73
    • 3.4.2 Market Limiters 73
  • 3.5 COMPETITIVE MARKET SHARE ANALYSIS 75
  • 3.6 MERGERS AND ACQUISITIONS 79
  • 3.7 COMPANY PROFILES 81
    • 3.7.1 Anika Therapeutics 81
    • 3.7.2 Bioventus 82
    • 3.7.3 DePuy Synthes 83
    • 3.7.4 Ferring Pharmaceuticals 84
    • 3.7.5 Fidia Pharmaceuticals 85
    • 3.7.6 Genzyme (Sanofi Group) 86
    • 3.7.7 Harvest Technologies (Terumo BCT) 87
    • 3.7.8 Integra LifeSciences 88
    • 3.7.9 Medtronic 89
    • 3.7.10 Musculoskeletal Transplant Foundation (MTF) 91
    • 3.7.11 NuVasive 92
    • 3.7.12 Orthofix 93
    • 3.7.13 RTI Surgical 94
    • 3.7.14 Stryker 95
    • 3.7.15 Vericel Corporation (formerly Aastrom Bioscience) 96
    • 3.7.16 Zimmer Biomet 97
  • 3.8 SWOT ANALYSIS 99
    • 3.8.1 Anika Therapeutics 99
    • 3.8.2 Bioventus 101
    • 3.8.3 DePuy Synthes 103
    • 3.8.4 Ferring Pharmaceuticals 104
    • 3.8.5 Fidia Pharmaceuticals 105
    • 3.8.7 Harvest Technologies (Terumo BCT) 107
    • 3.8.8 Integra LifeSciences 108
    • 3.8.9 Medtronic 109
    • 3.8.10 Musculoskeletal Transplant Foundation (MTF) 110
    • 3.8.11 NuVasive 111
    • 3.8.12 Orthofix 112
    • 3.8.14 Stryker 114
    • 3.8.15 Vericel Corporation (formerly Aastrom Bioscience) 115
    • 3.8.16 Zimmer Biomet 116

PROCEDURE NUMBERS 118

  • 4.1 INTRODUCTION 118
  • 4.2 PROCEDURES 119
    • 4.2.1 Orthopedic Biomaterial Procedures by Segment 119
    • 4.2.2 Orthopedic Bone Grafting Procedures 121
      • 4.2.2.1 Units per Procedure by Indication 123
      • 4.2.2.2 Autograft Orthopedic Bone Grafting Procedures by Indication 124
      • 4.2.2.3 Synthetic Orthopedic Bone Grafting Procedures by Indication 127
    • 4.2.3 Hyaluronic Acid Supplementation Procedures 130
      • 4.2.3.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle 130

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET 132

  • 5.1 INTRODUCTION 132
  • 5.2 MARKET ANALYSIS AND FORECAST 133
      • 5.2.1.1 Synthetic Bone Graft Substitute Market 133
      • 5.2.1.1.1 Synthetic Bone Graft Substitute Market by Indication 135
      • 5.2.1.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 161
  • 5.3 DRIVERS AND LIMITERS 162
    • 5.3.1 Market Drivers 162
    • 5.3.2 Market Limiters 162
  • 5.4 COMPETITIVE MARKET SHARE ANALYSIS 164

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET 167

  • 6.1 INTRODUCTION 167
    • 6.1.1 Benefits of Viscosupplementation 168
    • 6.1.2 Synovial Fluid 168
  • 6.2 MARKET OVERVIEW 169
  • 6.3 MARKET ANALYSIS AND FORECAST 175
    • 6.3.1 Total Hyaluronic Acid Viscosupplementation Market 175
    • 6.3.2 Three-Injection Hyaluronic Acid Viscosupplementation Market 177
    • 6.3.3 Five-Injection Hyaluronic Acid Viscosupplementation Market 179
  • 6.4 DRIVERS AND LIMITERS 181
    • 6.4.1 Market Drivers 181
    • 6.4.2 Market Limiters 181
  • 6.5 COMPETITIVE MARKET SHARE ANALYSIS 183

ABBREVIATIONS 187

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.